Patents by Inventor Justin Moser

Justin Moser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THREE-POINT HITCH ADAPTERS, ATTACHMENTS, BALE WRAP ROLLING ASSEMBLIES, AND RELATED METHODS OF USE
    Publication number: 20250089589
    Abstract: A three-point hitch adapter has: a structural frame; a three-point hitch connector at a leading end of the structural frame; a three-point hitch at a trailing end of the structural frame; and a fifth wheel coupling mounted on the structural frame. A bale wrap roller assembly has a structural frame; a hitch connector at a leading end of the structural frame; a wrap-receiving spool; and a motor connected to rotate the wrap-receiving spool.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 20, 2025
    Inventors: Chris Moser, Justin Moser, Tyran Shelton
  • Formulations for Cathepsin K Inhibitors with Vitamin D
    Publication number: 20160166529
    Abstract: The instant invention relates to pharmaceutical compositions comprising cathespin K inhibitors and Vitamin D.
    Type: Application
    Filed: July 7, 2014
    Publication date: June 16, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Majid MAHJOUR, Decheng MA, Christina Marie BACCI, Julianne Margaret FARABAUGH, Justin MOSER, Lixia CAI, Stephen L. CONWAY
  • Formulations for cathepsin K inhibitors
    Patent number: 8975296
    Abstract: The instant invention relates to pharmaceutical compositions containing cathespin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Grant
    Filed: March 20, 2013
    Date of Patent: March 10, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Haihong Fan, Majid Mahjour, Justin Moser, Bhagwant Rege
  • Formulations of suberoylanilide hydroxamic acid and methods for producing same
    Patent number: 8450372
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: May 28, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeannie Chow Wong, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Benjamin Max Cohen, Vincent R. Capodanno, Brian Sell, Thomas A. Miller
  • Formulations of suberoylanilide hydroxamic acid and methods for producing same
    Patent number: 8288440
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: October 16, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeannie Chow Wong, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Benjamin Max Cohen, Vincent R. Capodanno, Brian Sell
  • Formulations of suberoylanilide hydroxamic acid and methods for producing the same
    Patent number: 8093295
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: January 10, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jeannie Chow Wong, Benjamin Max Cohen, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Brian Sell, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Vincent R. Capodanno
  • CB-1 receptor modulator formulations
    Patent number: 8003672
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: August 23, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat
  • FORMULATIONS FOR CATHEPSIN K INHIBITORS
    Publication number: 20110065800
    Abstract: The instant invention relates to pharmaceutical compositions containing cathepsin K inhibitors. Also disclosed are processes for making said pharmaceutical compositions.
    Type: Application
    Filed: May 6, 2009
    Publication date: March 17, 2011
    Inventors: Haihong Fan, Majid Mahjour, Justin Moser, Bhagwant Rege
  • FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME
    Publication number: 20100119596
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Application
    Filed: January 13, 2010
    Publication date: May 13, 2010
    Inventors: Jeannie Chow Wong, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Benjamin Max Cohen, Vincent R. Capodanno, Brian Sell
  • FORMULATIONS OF SUBEROYLANILIDE HYDROXAMIC ACID AND METHODS FOR PRODUCING SAME
    Publication number: 20100112046
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Application
    Filed: January 13, 2010
    Publication date: May 6, 2010
    Inventors: Jeannie Chow Wong, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Benjamin Max Cohen, Vincent R. Capodanno, Brian Sell
  • CB-1 receptor modulator formulations
    Publication number: 20090264476
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabinoid inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 22, 2009
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat
  • CB-1 receptor modulator formulations
    Publication number: 20090264436
    Abstract: Described herein are solid, stable pharmaceutical formulations of cannabinoid receptor inverse agonists, such as taranabant, and processes of making such formulations. Additionally, described herein are solid stable pharmaceutical formulations of cannabiniod inverse agonists, such as taranabant, and an additional therapeutic agent, as well as processes for making such pharmaceutical formulations.
    Type: Application
    Filed: April 17, 2009
    Publication date: October 22, 2009
    Inventors: Craig McKelvey, Sarah Geers, Justin Moser, Bhagwant Rege, Dina Zhang, Sutthilug Sotthivirat
  • Formulations Of Suberoylanilide Hydroxamic Acid And Methods For Producing Same
    Publication number: 20080132575
    Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
    Type: Application
    Filed: May 16, 2006
    Publication date: June 5, 2008
    Inventors: Jeannie Chow Wong, Aaron S. Cote, Erik A. Dienemann, Kimberly Gallagher, Craig Ikeda, Justin Moser, Pavol Rajniak, Robert A. Reed, Cindy Starbuck, Hsien-Hsin Tung, Qingxi Wang, Benjamin Max Cohen, Vincent R. Capodanno, Brian Sell, Thomas A. Miller